212 related articles for article (PubMed ID: 36639382)
1. CD4
Lei X; Khatri I; de Wit T; de Rink I; Nieuwland M; Kerkhoven R; van Eenennaam H; Sun C; Garg AD; Borst J; Xiao Y
Nat Commun; 2023 Jan; 14(1):217. PubMed ID: 36639382
[TBL] [Abstract][Full Text] [Related]
2. CD4
Lei X; de Groot DC; Welters MJP; de Wit T; Schrama E; van Eenennaam H; Santegoets SJ; Oosenbrug T; van der Veen A; Vos JL; Zuur CL; de Miranda NFCC; Jacobs H; van der Burg SH; Borst J; Xiao Y
Cell Mol Immunol; 2024 Apr; 21(4):374-392. PubMed ID: 38383773
[TBL] [Abstract][Full Text] [Related]
3. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
4. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
5. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
6. Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.
He F; Wu Z; Liu C; Zhu Y; Zhou Y; Tian E; Rosin-Arbesfeld R; Yang D; Wang MW; Zhu D
Signal Transduct Target Ther; 2024 May; 9(1):139. PubMed ID: 38811552
[TBL] [Abstract][Full Text] [Related]
7. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
8. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
9. In Situ Hydrogel Modulates cDC1-Based Antigen Presentation and Cancer Stemness to Enhance Cancer Vaccine Efficiency.
Gao T; Yuan S; Liang S; Huang X; Liu J; Gu P; Fu S; Zhang N; Liu Y
Adv Sci (Weinh); 2024 May; 11(20):e2305832. PubMed ID: 38564766
[TBL] [Abstract][Full Text] [Related]
10. Type 1 conventional dendritic cells and interferons are required for spontaneous CD4
Mattiuz R; Brousse C; Ambrosini M; Cancel JC; Bessou G; Mussard J; Sanlaville A; Caux C; Bendriss-Vermare N; Valladeau-Guilemond J; Dalod M; Crozat K
Clin Transl Immunology; 2021; 10(7):e1305. PubMed ID: 34277006
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
[TBL] [Abstract][Full Text] [Related]
13. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
14. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
15. Profiling MHC II immunopeptidome of blood-stage malaria reveals that cDC1 control the functionality of parasite-specific CD4 T cells.
Draheim M; Wlodarczyk MF; Crozat K; Saliou JM; Alayi TD; Tomavo S; Hassan A; Salvioni A; Demarta-Gatsi C; Sidney J; Sette A; Dalod M; Berry A; Silvie O; Blanchard N
EMBO Mol Med; 2017 Nov; 9(11):1605-1621. PubMed ID: 28935714
[TBL] [Abstract][Full Text] [Related]
16. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
17. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.
Zhang M; Yang W; Wang P; Deng Y; Dong YT; Liu FF; Huang R; Zhang P; Duan YQ; Liu XD; Lin D; Chu Q; Zhong B
Nat Commun; 2020 Nov; 11(1):6119. PubMed ID: 33257678
[TBL] [Abstract][Full Text] [Related]
18. A distinct stimulatory cDC1 subpopulation amplifies CD8
Meiser P; Knolle MA; Hirschberger A; de Almeida GP; Bayerl F; Lacher S; Pedde AM; Flommersfeld S; Hönninger J; Stark L; Stögbauer F; Anton M; Wirth M; Wohlleber D; Steiger K; Buchholz VR; Wollenberg B; Zielinski CE; Braren R; Rueckert D; Knolle PA; Kaissis G; Böttcher JP
Cancer Cell; 2023 Aug; 41(8):1498-1515.e10. PubMed ID: 37451271
[TBL] [Abstract][Full Text] [Related]
19. Conventional Type 1 Dendritic Cells in Intestinal Immune Homeostasis.
Sasaki I; Kato T; Hemmi H; Fukuda-Ohta Y; Wakaki-Nishiyama N; Yamamoto A; Kaisho T
Front Immunol; 2022; 13():857954. PubMed ID: 35693801
[TBL] [Abstract][Full Text] [Related]
20. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
